L-4F Inhibits Lipopolysaccharide-Mediated Activation of Primary Human Neutrophils
Authors:
- 20 March 2014
- journal article
- research article
- Published by Springer Nature in Inflammation
- Vol. 37 (5) , 1401-1412
Abstract
Human apolipoprotein A-I (apoA-I) mimetic L-4F inhibits acute inflammation in endotoxemic animals. Since neutrophils play a crucial role in septic inflammation, we examined the effects of L-4F, compared to apoA-I, on lipopolysaccharide (LPS)-mediated activation of human neutrophils. We performed bioassays in human blood, isolated human neutrophils (incubated in 50 % donor plasma), and isolated human leukocytes (incubated in 5 and 50 % plasma) in vitro. In whole blood, both L-4F and apoA-I inhibited LPS-mediated elevation of TNF-α and IL-6. In LPS-stimulated neutrophils, L-4F and apoA-I (40 μg/ml) also decreased myeloperoxidase and TNF-α levels; however, L-4F tended to be superior in inhibiting LPS-mediated increase in IL-6 levels, membrane lipid rafts abundance and CD11b expression. In parallel experiments, when TNF-α and IL-8, instead of LPS, was used for cell stimulation, L-4F and/or apoA-I revealed only limited efficacy. In LPS-stimulated leukocytes, L-4F was as effective as apoA-I in reducing superoxide formation in 50 % donor plasma, and more effective in 5 % donor plasma (P < 0.05). Limulus ambocyte lysate (LAL) and surface plasmon resonance assays showed that L-4F neutralizes LAL endotoxin activity more effectively than apoA-I (P < 0.05) likely due to avid binding to LPS. We conclude that (1) direct binding/neutralization of LPS is a major mechanism of L-4F in vitro; (2) while L-4F has similar efficacy to apoA-I in anti-endotoxin effects in whole blood, it demonstrates superior efficacy to apoA-I in aqueous solutions and fluids with limited plasma components. This study rationalizes the utility of L-4F in the treatment of inflammation that is mediated by endotoxin-activated neutrophils.Keywords
This publication has 60 references indexed in Scilit:
- Anti-Inflammatory Mechanisms of Apolipoprotein A-I Mimetic Peptide in Acute Respiratory Distress Syndrome Secondary to SepsisPLOS ONE, 2013
- Sidedness of interfacial arginine residues and anti-atherogenicity of apolipoprotein A-I mimetic peptidesJournal of Lipid Research, 2012
- Enhancement by LDL of transfer of L-4F and oxidized lipids to HDL in C57BL/6J mice and human plasmaJournal of Lipid Research, 2011
- Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orallyJournal of Lipid Research, 2011
- Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL functionJournal of Lipid Research, 2011
- The apolipoprotein A-I mimetic peptide 4F prevents defects in vascular function in endotoxemic ratsJournal of Lipid Research, 2010
- Apolipoprotein A-I mimetic 4F alters the function of human monocyte-derived macrophagesAmerican Journal of Physiology-Cell Physiology, 2010
- Modification of High Density Lipoprotein by Myeloperoxidase Generates a Pro-inflammatory ParticleJournal of Biological Chemistry, 2009
- Apolipoprotein A-I mimetic peptide treatment inhibits inflammatory responses and improves survival in septic ratsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patientsJournal of Lipid Research, 2008